Preferred Label : Narlumosbart;
NCIt synonyms : Anti-RANKL Monoclonal Antibody JMT103;
NCIt definition : A recombinant, human, immunoglobulin G4 (IgG4) monoclonal antibody directed against
the receptor activator of nuclear factor kappa beta ligand (RANKL), with potential
antiosteoclast and bone-sparing activities. Upon administration, narlumosbart specifically
binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on
osteoclast cell surfaces. This may inhibit osteoclast activity, decrease bone resorption,
increase bone mineral density, and may protect bones from tumor metastasis. This may
abrogate hypercalcemia of malignancy and may correct serum calcium levels. RANKL,
a protein expressed by osteoblastic cells, plays an important role in osteoclastic
differentiation and activation. Both RANKL and RANK are overexpressed in certain bone
tumors, and the RANK/RANKL-mediated signaling pathway plays an important role in certain
bone tumors.;
UNII : J38KT46AH8;
CAS number : 2646587-68-8;
Molecule name : JMT 103; JMT-103;
NCI Metathesaurus CUI : CL1798893;
Origin ID : C190458;
UMLS CUI : C5783725;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
